Replies to post #510290 on NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

FALSE, Read it again -- this was is JAMA one of the most respected journals in the world:
"The five-year survival rate increased from five percent to 13 percent for patients treated with Optune together with temozolomide versus patients treated with temozolomide alone. These are the best results reported for newly diagnosed GBM patients in a phase 3 trial to date and represent a new landmark for five-year survival rate in this difficult to treat disease."

Novocure Presentation - Slide 10:
https://www.novocure.com/wp-content/uploads/2022/07/NVCR_Corporate_Presentation_July-2022.pdf

[Umibe5690]

It should be noted that even Roger Stupp officially stated in a presentation made in October, 2020, if I recall the approximate date correctly, that long term data provided in connection with Optune could not be relied upon because no follow up had been done. Accordingly, and in other words, Optune’s long term “data” could not be relied upon.

Dr. Stupp, as a PI in the Optune clinical trial, originally wrote the JA in NEJM as a lead author. Dr Stupp has since been a consultant for NWBO and has so acknowledged this relationship.